Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU

February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M.D., Vice President, Clinical Development and Global Medical Affairs, Janssen Research & Development, LLC. “This year, we look forward to presenting data from our robust prostate cancer development program, including analyses of the Phase 3 ACIS and TITAN studies, which underscore the clinical value of our portfolio for patients today and set the stage for the next generation of therapies in our pipeline.”New Analyses for ERLEADA® Highlight Breadth of Ongoing Clinical Development ProgramData from three Phase 3 registrational clinical trials will be featured in oral presentations:ACIS: Analysis evaluating ERLEADA® (apalutamide) in combination with ZYTIGA® (abiraterone acetate) plus prednisone versus abiraterone acetate plus prednisone in patients with chemo-naïve metastatic castration-resistant prostate cancer (Abstract #9)TITAN: Final analysis wi...

Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news